Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
CMet/AXL Selective Inhibitor by BioSeedin for Gastric Cancer: Likelihood of Approval
CMet/AXL Selective Inhibitor is under clinical development by BioSeedin and currently in Phase I for Gastric Cancer. According to GlobalData,...